Protagenic Therapeutics Cash Flow Quality Index
Protagenic Therapeutics cash flow quality index. Protagenic Therapeutics (PTIX) has a Cash Flow Quality Index of -0.07x as of December 2025. Operating cash flow of $-410.42K is below net income of $5.83 Million, suggesting accrual-heavy earnings not yet converted to cash. See how financially flexible is Protagenic Therapeutics to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Protagenic Therapeutics (1998–2006)
Cash flow quality index of Protagenic Therapeutics from 1998 to 2006. Historical Cash Flow Quality Index for Protagenic Therapeutics across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore PTIX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Protagenic Therapeutics Cash Flow Quality Index by Year (1998–2006)
Protagenic Therapeutics cash flow quality index by year from 1998 to 2006. Year-by-year earnings quality comparison for Protagenic Therapeutics. For the full cash flow conversion analysis, see Protagenic Therapeutics cash conversion from operations.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2006 | 1.38x | $931.00K | $677.00K | ▼ -86.8% |
| 2001 | 10.44x | $1.50 Million | $144.00K | ▲ +238.2% |
| 2000 | 3.09x | $3.51 Million | $1.14 Million | ▲ +561.1% |
| 1998 | -0.67x | $-434.00K | $648.00K | — |